however, no research has yet examined the communication between owners and professionals about equine weight. In other fields, the use of behaviour change principles and communication skills have been shown to improve compliance with health related behaviour change in human and veterinary medicine.
Results: Owner priorities often appeared to be at odds with the concerns of professionals; owners perceived weight management to be embedded within their management of multiple, often conflicting, aspects such as the horse's emotional and physical wellbeing, yard restrictions, and their own lifestyle, and hence behaviour change was complex. Conversely, many professionals perceived themselves as purveyors of information and felt that a 'directive' approach to weight management should encourage the owner to make changes. Professionals who were able to communicate effectively about obesity were those who employed a collaborative approach, building a relationship with the individual and taking time to discuss proposed strategies for change.
Main limitations:
This study utilised interviews which were retrospective of consultations; it would be valuable to compare the language used in real-life conversations through observation.
Conclusions:
Time spent by professionals building relationships with owners and the application of communication skills consistent with the principles of behaviour change were received positively by horseowners and assisted them in changing their behaviour; this information could be useful for equine professionals who wish to consult with owners on complex management issues. Main limitations: Small sample size and lack of cross-validation of cutoff points on independent, 'unseen' data.
Conclusions: Accelerometry can distinguish activities in grazing horses repeatably. Our proof-of-concept study demonstrates modifying pasture management influences activity, opening avenues for studies into obesity management. Methods: Clinical records of 19 ponies that had been refractory to treatment with the licensed pergolide tablet and were subsequently treated with a palatable pergolide paste (BOVA UK) were reviewed and clinical and endocrinological data were analysed. PPID was diagnosed if there were clinical signs and adrenocorticotropic hormone (ACTH) concentration was >50 pg/mL in July (10 ponies, NAUT group) or >100 pg/mL from August to October (9 ponies, AUT group). All ponies were re-examined after 1 month of treatment, in October, November and after 6 months of treatment to ensure pergolide doses were appropriate through changing seasons; dose rates were adjusted as necessary.
Results: ACTH concentrations improved significantly with treatment and returned to within reference range in 14/19 cases (74%). Median ACTH concentration improved from 110 to 37 pg/mL (NAUT group) and from 206 to 25 pg/mL (AUT group). There was no significant difference in insulin concentration in association with treatment in either group. Clinical signs (44 signs in 19 ponies) improved markedly, mildly, did not improve or deteriorated in 31%, 12%, 43%, 4% and 10%, respectively. There were no clinically relevant changes on haematological or clinical chemical examinations following treatment. One pony developed laminitis on treatment, two became inappetant (which resolved with dose reduction) and one pony refused to eat the paste.
Main limitations: Small numbers. Treating vets were not blinded.
The palatable pergolide paste preparation was effective and safe in ponies with PPID. Methods: An electronic survey was developed, trialled, and distributed through email distribution lists; consent was implied through active participation. Data are presented as median scores. Differences between responses were compared using chi-squared analysis.
Results: 166 respondents completed the survey. The majority of respondents (66.9%) use gentamicin, with specialists using it more frequently than nonspecialists (P<0.0001). Amikacin was used by 59.6% of respondents; frequency of use was less than for gentamicin (P<0.0001). Gentamicin was used intravenously, by inhalation and IVRA (65.1%, 18.6% and 28.3%, respectively), more frequently than amikacin by these routes (30.1%, 3.4% and 19.3%). Amikacin was used more than gentamicin intra-articularly (51.8% vs. 24.1%). Bacterial sensitivity was used prior to use of gentamicin for 35.9% of responses to 20 clinical scenarios across the respondents. First line empirical use was selected for 74.2% of responses that did not include lower airway infection. Majority of respondents used gentamicin at a dose of 6.6 mg/kg bwt, with higher doses being described by 13.7% of respondents for use in the otherwise healthy adult, 18.5% when treating the adult with sepsis, 65% when treating the otherwise healthy foal and 48.5% when treating the foal with sepsis. Methods: Records were reviewed to identify all horses and ponies admitted to a single equine hospital between 2005 and 2016 that underwent therapeutic drug monitoring of plasma gentamicin concentration. Clinical records were reviewed to obtain patients' age, sex, breed, date of admission, date of gentamicin assay, peak plasma gentamicin concentration, trough plasma gentamicin concentration, serum urea concentration, serum creatinine concentration and current diagnosis. A linear mixed effects model was produced to consider the influences of age, sex, breed and current diagnosis on peak plasma gentamicin concentration.
Results: Peak and trough plasma gentamicin concentrations were available for 229 patients. Horses aged less than 1 year old and horses with respiratory disease had lower peak plasma gentamicin concentrations than all other groups (P<0.01 and P<0.01). All extrapolated 24-h trough plasma gentamicin concentrations were less than 0.5-2 lg/mL.
Main limitations: Serum urea and creatinine concentrations after gentamicin treatment were not available for all patients. Patients that had more than one concurrent disease process were grouped together, and not included in the separate disease groups.
Patient age and disease status should be considered when calculating initial gentamicin dose. Therapeutic drug monitoring allows for gentamicin dose adjustment, which may be particularly important in young horses and those with respiratory disease. 
